Effect of dexmedetomidine on platelet aggregation in whole blood

Effect of dexmedetomidine on platelet aggregation in whole blood - Dexmedetomidine and platelet aggregation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030233

Enrollment

Registered

2017-12-03

Start date

2017-12-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy volunteer

Interventions

administration of dexmedetomidine (10 nM) in whole blood ex vivo administration of dexmedetomidine (100 nM) in whole blood ex vivo administration of normal saline in whole blood ex vivo

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: healthy volunteer, non-smoker

Exclusion criteria

Exclusion criteria: smoker, those who are treated with anticoagulant or anti platelet therapy

Design outcomes

Primary

Measure	Time frame
MAADP measured with TEG6s and PlateletMapping	—

Secondary

Measure	Time frame
MAHKH, MAActF, %AggregationADP, R, angle, K measured with TEG6s and PlateletMapping	—

Countries

Japan

Contacts

Public ContactYusuke Yoshikawa

Sapporo Medical University School of Medicine Anesthesiology

y.yoshikawa@sapmed.ac.jp011-688-9663

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026